Over the past six months, Merck’s share price climbed 41%, powered by a 4% year-over-year revenue increase to $15.2 billion in its latest quarterly report and a 12% rise in net income to $5.1 billion. Investors have responded positively to the company’s ability to expand its operating margin by 150 basis points through cost-efficiency measures in manufacturing and supply chain optimization. Confidence has also been bolstered by updated guidance for full-year revenue growth of 5% to 6% and adjusted earnings per share of $6.50 to $6.70, reflecting stronger cash flow generation and a commitment to share repurchases and dividends.

With Keytruda’s growth remaining important but increasingly well-understood, Merck is shifting investor focus to its newer non-oncology launches. Capvaxive, an mRNA-based vaccine candidate targeting respiratory syncytial virus, is expected to contribute $200 million in Q4 sales following its September launch in the United States and Europe. Winrevair, an inhaled therapy for chronic obstructive pulmonary disease, enters the market in November with a projected first-year revenue run rate of $150 million. Meanwhile, the Animal Health segment delivered an 8% sales increase to $1.4 billion in the prior quarter, led by strong demand for its livestock vaccines and companion animal parasitic treatments.

Merck’s Board of Directors has approved a quarterly dividend of $0.85 per share for the second quarter of 2026, payable on April 7, 2026, to holders of record as of March 16. This marks the 42nd consecutive year of dividend increases for the company, underscoring its commitment to returning capital to shareholders. At the current pace, dividend distributions account for roughly 30% of annual free cash flow, leaving ample room for ongoing investment in R&D and strategic acquisitions.

Looking beyond 2026, Merck is advancing a mid-stage pipeline that includes CD388, a bispecific antibody targeting hematological malignancies, now in global Phase II trials with top-line data expected in mid-2027. The recently approved subcutaneous formulation of Keytruda is on track for a broader rollout in early 2026, offering faster administration and potential payer support ahead of Keytruda’s primary patent expirations in 2028. Analysts estimate that these initiatives could offset up to $3 billion in annual revenue loss from biosimilar competition entering post-2028.